Journal of Vaccine Research 2024, Vol.14, No.5, 217-230 http://medscipublisher.com/index.php/jvr 221 Multi-pathogen vaccines must demonstrate that they can be administered safely, both in the short term and over extended periods, while maintaining a robust immunogenic response to each targeted pathogen (Hsieh et al., 2021). 4.1 Common safety issues of multi-pathogen vaccines Common safety issues related to multi-pathogen vaccines generally mirror those of single-pathogen vaccines, but with additional considerations due to the increased complexity. Typical side effects include local reactions at the injection site, such as pain, redness, or swelling, as well as systemic symptoms like fever, headache, and fatigue. These are usually mild and transient, resolving within a few days after vaccination. In clinical trials, multi-pathogen vaccines like the combined COVID-19 vaccines have shown similar safety profiles to single-target vaccines, with most adverse reactions being mild to moderate (Voysey et al., 2020). However, multi-pathogen vaccines may also introduce additional complexities, such as potential immune interference, where the immune system may respond unevenly to the multiple antigens presented. This could result in a lower immune response to one or more of the pathogens in the vaccine, potentially reducing the overall effectiveness. In some cases, the inclusion of adjuvants (substances that enhance the immune response) in multi-pathogen vaccines may lead to stronger side effects, including more pronounced local or systemic reactions (Polack et al., 2020). 4.2 Issues related to immunogenicity Immunogenicity, the ability of a vaccine to provoke an immune response, is a critical factor in assessing vaccine safety and efficacy. In the case of multi-pathogen vaccines, balancing the immune response to multiple antigens without inducing immune interference or overloading the immune system is a key challenge. Studies have shown that while most multi-pathogen vaccines effectively generate immune responses to all included antigens, there are concerns that immune responses to some antigens may be less robust than expected (Flacco et al., 2018). For example, early trials of combination vaccines such as DTP (diphtheria, tetanus, and pertussis) highlighted the possibility of immune interference, where the immune response to one antigen might be suppressed due to the presence of others (Malfertheiner et al., 2018). More recent vaccines, including the multi-antigenic vaccines targeting COVID-19 variants, have managed to mitigate such interference through optimized formulations, but immunogenicity remains a critical aspect of ongoing vaccine development. To address these challenges, some multi-pathogen vaccines include adjuvants to enhance the overall immune response. However, while adjuvants can boost the vaccine's effectiveness, they may also increase the risk of local and systemic adverse reactions, making it essential to carefully balance immunogenicity and safety (Heath et al., 2021). 4.3 Long-term safety data Long-term safety data are essential for assessing the potential risks of multi-pathogen vaccines over time, particularly as these vaccines may be given in multiple doses or boosters. Monitoring the occurrence of adverse events and the durability of the immune response is crucial to ensure that these vaccines continue to be safe and effective years after administration. While some long-term safety data for traditional combination vaccines (such as MMR and DTP) are available, newer multi-pathogen vaccines like those for COVID-19 are still in the process of accumulating long-term safety data. Preliminary data from long-term studies of multi-pathogen vaccines like the mRNA-based COVID-19 vaccines show that serious adverse events are rare, and the vaccines continue to provide protection over time without significant safety concerns (Baden et al., 2020). However, given the relatively recent introduction of many multi-pathogen vaccines, ongoing surveillance and studies are needed to detect any rare, long-term side effects that may arise, such as autoimmune reactions or chronic inflammation. Furthermore, long-term monitoring is crucial for understanding the vaccine's impact on various population groups, including immunocompromised individuals, pregnant women, and the elderly, who may respond differently to
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==